083790.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 13:01):
Our systems believe the stock currently is undervalued by 0.22% compare to its pairs and should correct upwards.

Stats
今日成交量	54 100
平均成交量	199 147
市值	203.38B
EPS	KRW-98.15 ( Q1 \| 2024-03-31 )
下一个收益日期	( KRW0 ) 2024-08-14
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW4.10 (0.15%)

相关性 (AI algo v.1.1b): Undervalued: 0.22% KRW2 751.11 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: 0.20 (neutral)

短: 0.00 (neutral)

Signal:(48.113) Neutral

CrystalGenomics, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CrystalGenomics, Inc. 相关性 - 货币/商品

-0.22
( neutral )

0.46
( neutral )

-0.81
( strong negative )

-0.11
( neutral )

-0.73
( moderate negative )

0.65
( weak )

CrystalGenomics, Inc. 财务报表

Annual	2023
营收:	KRW4.88B
毛利润:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
营收:	KRW4.88B
毛利润:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
营收:	KRW17.46B
毛利润:	KRW9.07B (51.96 %)
EPS:	KRW132.36

FY	2022
营收:	KRW16.25B
毛利润:	KRW8.47B (52.13 %)
EPS:	KRW117.19

Financial Reports:

No articles found.

CrystalGenomics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CrystalGenomics, Inc.

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.